Skip to main content
Top
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Letter

Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?

Authors: Nina Buchtele, Michael Schwameis, Bernd Jilma

Published in: Critical Care | Issue 1/2018

Login to get access

Excerpt

A recent structured review by Busse et al. confirmed the efficacy of angiotensin II in terms of increasing blood pressure in patients with different types of shock [1]. The majority of data for this analysis came from the recently published ATHOS-3 trial which showed that angiotensin II effectively increased blood pressure in patients with vasodilatory shock receiving high-dose vasopressors [2]. In this trial, safety was defined as the secondary outcome. Considering the similar total number of adverse events in both groups, the administration of angiotensin II seemed safe. Antonucci et al. had already raised some caution about the administration of angiotensin II [3]. In addition, we want to add some further comments about the use of angiotensin II, especially as it has recently been approved by the US Food and Drug administration. …
Literature
1.
go back to reference Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care. 2017;21(1):324.CrossRefPubMedPubMedCentral Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care. 2017;21(1):324.CrossRefPubMedPubMedCentral
2.
go back to reference Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–30.CrossRefPubMed Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–30.CrossRefPubMed
4.
go back to reference Lamontagne F, Meade MO, Hebert PC, Asfar P, Lauzier F, Seely AJE, Day AG, Mehta S, Muscedere J, Bagshaw SM, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med. 2016;42(4):542–50.CrossRefPubMed Lamontagne F, Meade MO, Hebert PC, Asfar P, Lauzier F, Seely AJE, Day AG, Mehta S, Muscedere J, Bagshaw SM, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med. 2016;42(4):542–50.CrossRefPubMed
5.
go back to reference Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, Lipman J, Jensen JU, Myburgh J, Singer M, Bellomo R, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med. 2016;42(12):1958–69.CrossRefPubMed Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, Lipman J, Jensen JU, Myburgh J, Singer M, Bellomo R, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med. 2016;42(12):1958–69.CrossRefPubMed
6.
go back to reference Busse LW, Wang XS, Chalikonda DM, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285–94.CrossRefPubMedPubMedCentral Busse LW, Wang XS, Chalikonda DM, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285–94.CrossRefPubMedPubMedCentral
7.
go back to reference Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.PubMedPubMedCentral Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.PubMedPubMedCentral
8.
go back to reference Sviri S, Hashoul J, Stav I, et al. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care. 2014;29(1):157–60.CrossRefPubMed Sviri S, Hashoul J, Stav I, et al. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care. 2014;29(1):157–60.CrossRefPubMed
Metadata
Title
Angiotensin II for the treatment of vasodilatory shock: enough data to consider angiotensin II safe?
Authors
Nina Buchtele
Michael Schwameis
Bernd Jilma
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2006-0

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue